carmot glp-1 Roche's GLP1/GIP drug sees 22.5% weight loss, readies ph. 3 push Roche buys Carmot Therapeutics, Inc.

doi: 10.1186/s12933-025-02607-w 32 BaggioLLYustaBMulvihillEECaoXStreutkerCJButanyJet al

Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition

Safety Profile Well-Tolerated : Semaglutide is generally well-tolerated, with common side effects being gastrointestinal, such as nausea and vomiting, which typically decrease over time

Phase 2 Clinical Trial# The Phase 2 trial enrolled 469 adults with obesity or overweight and evaluated three subcutaneous dose levels of CT-388 versus placebo over 48 weeks

Why Immune Function Matters Here It is easy to get tunnel vision on the scale